American biopharmaceutical company, Gilead Sciences has opened new offices in Dubai, as part of expanding its regional footprint.
The new offices reflect the expansion of its portfolio into therapeutic areas such as COVID-19 and oncology. The inauguration in the UAE follows the recent opening of Gilead Sciences offices in Riyadh.
The new Dubai offices are located at One Central, Central Business District, Dubai World Trade Centre, moving from its previous address in Dubai Healthcare City.
Furthermore, the new offices of Gilead Sciences were designed to reflect Dubai’s status as a global center of business further to the cultural diversity of the UAE and surrounding Gulf region.
Frederico Silva General Manager Gilead Sciences – Middle East
“Committed to grow as an employer of choice, our investments in state-of-the-art spaces to house our talent is reflective of our core values that guide our steadfast mission of developing and delivering innovative therapies within HIV, cancer, COVID-19, and viral hepatitis. In our vision to create a healthier world for all people, delivering innovative medicines that aim to prevent, treat and cure life-threatening diseases, we are guided by a philosophy that by investing in our employee experience further we are able to better serve our patient communities.”
Dr. Jacopo Andreose, Senior Vice President, Intercontinental and Global Patient Solutions at Gilead Sciences, said that, “The pharmaceutical sector in the UAE is benefitting from a steady rise in population and net income and the roll-out of the mandatory health insurance scheme. The healthcare industry is marked by continued improvement and strategic investments in high-quality medical services by the leadership.”
“We are keen on growing our presence in the UAE and wider region and will continue to invest in infrastructure and talent to best capitalize on these positive trends and to deliver upon the promise of our bold and transformative science,” Dr. Andreose added.
